YD Bio Ltd is a biopharmaceutical company engaged in blood based cancer detection, the development of stem cell and exosome based therapeutics, and the supply of clinical testing drugs for pharmaceutical partners. The company also pursues eye disease treatment products through its licensed technology from 3D Global Biotech. Its core activities focus on creating noninvasive diagnostic tests that analyze circulating cell free DNA methylation patterns to detect cancers such as pancreatic and breast malignancies. In parallel YD Bio Ltd seeks to advance regenerative therapies that utilize mesenchymal stem cells and exosomes for ocular conditions like dry eye disease and glaucoma. The firm operates primarily from Taiwan with a growing presence in the United States through a CLIA certified laboratory owned by its partner EG BioMed.

YD Bio Ltd generates revenue principally from fees received for supplying clinical trial materials and services to pharmaceutical companies. The firm has service agreements with Novartis Taiwan and Alcon Services AG Taiwan Branch under which it receives monthly payments for delivering pharmaceutical products, medical devices and laboratory equipment. Additionally the company anticipates future income from the commercialization of its blood based cancer detection tests which will be offered as laboratory developed tests to licensed health care providers. Revenue may also arise from the sale of eye disease therapeutic products such as exosome based eye drops and contact lenses once they complete clinical development and obtain regulatory clearance.

YD Bio Ltd occupies a niche position in the cancer diagnostics sector where it leverages a licensed cfDNA methylation platform that combines high throughput array technology with artificial intelligence driven biomarker selection. This approach yields tests with reported sensitivity above ninety percent and specificity exceeding ninety percent for pancreatic and breast cancer detection. Major competitors in the liquid biopsy space include Guardant Health Exact Sciences Freenome and Burning Rock Biotech which possess larger scale operations and broader product pipelines. YD Bio Ltd differentiates itself through its partnership with EG BioMed which provides access to a proprietary methylation database and a CLIA and CAP accredited U. S. laboratory enabling rapid test deployment. In the ophthalmic therapeutics arena the company competes with established players such as Johnson & Johnson Alcon and Regeneron Pharmaceuticals. Its competitive edge stems from the use of limbal stem cell derived exosomes which are naturally secreted and retain intrinsic bioactivity without genetic modification. This technology underpins products like exosome infused contact lenses and regenerative eye drops that aim to address dry eye disease glaucoma and corneal repair with a mechanism of action distinct from conventional drug based therapies.

YD Bio Ltd serves a diverse customer base that includes pharmaceutical companies requiring clinical trial supplies licensed health care providers ordering cancer screening tests and eventual consumers of eye disease products. Specific corporate customers identified in its filing are Novartis Taiwan and Alcon Services AG Taiwan Branch which together accounted for over fifty percent of the company’s revenue in recent years. The company’s cancer detection tests are marketed to physicians and clinics that prescribe the laboratory developed test for patient sampling. In the eye disease segment YD Bio Ltd intends to sell its products through pharmacies optometry practices and charity foundations that support vision health initiatives.